Francesco Martorana appointed CEO of Generali Insurance Asset Management

Francesco Martorana is the new Chief Executive Officer of Generali Insurance Asset Management S.p.A. Società di gestione del risparmio (GIAM), effective April 1st, 2019.

  • Santo Borsellino is appointed Chairman of the Board of Generali Insurance Asset Management S.p.A. Società di gestione del risparmio (GIAM), and takes on a new role within the business unit Generali Investments, Asset & Wealth Management  

 

Milan – Francesco Martorana is the new Chief Executive Officer of Generali Insurance Asset Management S.p.A. Società di gestione del risparmio (GIAM), effective April 1st, 2019.
Martorana also keeps, ad interim, his current role as Head of Investments at GIAM, which he covers since October 2017. Martorana joined the Generali Group in November 2013 as the Head of Group Asset Liability Management & Strategic Asset Allocation (ALM/SAA) for the general account assets. Prior to Generali, he held several management positions at Allianz Group, both in Italy and Germany.
A CFA and CAIA Charterholder, he holds a Master Degree in Finance from Università Commerciale Bocconi in Milan.

Santo Borsellino, who held the CEO role at Generali Insurance Asset Management S.p.A. Società di gestione del risparmio (the new name of the former Generali Investments Europe S.p.A. Società di gestione del risparmio) since June 2013, is taking on the Chairmanship of the Board of GIAM. In addition, he is appointed Head of Investments & Asset Management Corporate Governance Implementation & Institutional Relations, with the responsibility of managing the relations with external institutions, associations and regulatory bodies, and assuring effective implementation of the governance set-up of the business unit Generali Investments, Asset & Wealth Management.

INCORPORATING QUANT SIGNALS INTO EU EQUITY SECTOR/STYLE STRATEGY: MAINTAIN A TILT TO CYCLICALS AND VALUE

RELATED INSIGHTS

COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients. Gilead Sciences has questioned the findings of the WHO study saying data appeared inconsistent.
INCORPORATING QUANT SIGNALS INTO EU EQUITY SECTOR/STYLE STRATEGY: MAINTAIN A TILT TO CYCLICALS AND VALUE
We present an update of our proprietary equity valuation tool, based on quant models. It provides indications of over- or undervaluation for different sectors and styles of European equities, which is further enriched by our qualitative analysis. Currently, among European equity sectors, financials, energy, telecoms, and autos look undervalued while Pharma, utilities and software appear overvalued.
CHINA’S RECOVERY CONTINUED BUT A BIT SOFTER THAN EXPECTED
China's economic recovery continued in Q3 2020, although a bit softer than expected. Real GDP growth rose to 4.9% yoy, slightly below the Reuters consensus expectation of 5.2% yoy, but still a substantial upturn from the 3.2% yoy in Q2. On a quarterly base, growth dynamics softened to 2.7% qoq, after 11.7% qoq and -10% qoq in the two previous quarters.